NewsBenzingaLa CEO de Sanofi, Belen Garijo, dice que más allá de 2030, se espera que los ingresos totales se vean afectados solo moderadamente por la pérdida de exclusividad de Dupixent. La CEO de Sanofi, Belen Garijo, dice que más allá de 2030, se espera que los ingresos totales se vean afectados solo moderadamente por la pérdida de exclusividad de Dupixent. Benzinga 2026.10.30 13:08 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform Quanterix Affirms FY2026 Sales Guidance of $142.000M-$146.000M vs $143.357M Est
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform